Catabasis Pharmaceuticals Inc. (CATB) is primed for evolution with the beta value of 1.99

Catabasis Pharmaceuticals Inc. (CATB) is priced at $1.33 after the most recent trading session. At the very opening of the session, the stock price was $1.32 and reached a high price of $1.38, prior to closing the session it reached the value of $1.33. The stock touched a low price of $1.27.

Recently in News on October 26, 2020, Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy. — PolarisDMD Trial Did Not Achieve Primary or Secondary Endpoints –. You can read further details here

My Next COVID-19 Stock Alert Poised For Triple Digit Moves

Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.    

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<


Catabasis Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $8.5900 on 08/24/20, with the lowest value was $1.2500 for the same time period, recorded on 11/02/20.

Catabasis Pharmaceuticals Inc. (CATB) full year performance was -74.76%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Catabasis Pharmaceuticals Inc. shares are logging -84.52% during the 52-week period from high price, and 6.40% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.25 and $8.59.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1353287 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Catabasis Pharmaceuticals Inc. (CATB) recorded performance in the market was -77.50%, having the revenues showcasing -79.38% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 26.31M, as it employees total of 27 workers.

Analysts verdict on Catabasis Pharmaceuticals Inc. (CATB)

During the last month, 3 analysts gave the Catabasis Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 6.1535, with a change in the price was noted -5.5576. In a similar fashion, Catabasis Pharmaceuticals Inc. posted a movement of -80.90% for the period of last 100 days, recording 701,210 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CATB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Catabasis Pharmaceuticals Inc. (CATB): Technical Analysis

Raw Stochastic average of Catabasis Pharmaceuticals Inc. in the period of last 50 days is set at 1.04%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 1.17%. In the last 20 days, the company’s Stochastic %K was 1.40% and its Stochastic %D was recorded 1.57%.

Let’s take a glance in the erstwhile performances of Catabasis Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -77.50%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -77.68%, alongside a downfall of -74.76% for the period of the last 12 months. The shares increased approximately by -6.99% in the 7-day charts and went up by -79.57% in the period of the last 30 days. Common stock shares were lifted by -79.38% during last recorded quarter.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free